Total Payments
$1.9M
2024 Payments
$481,027
Companies
32
Transactions
1,680
Medicare Patients
899
Medicare Billing
$426,227
Payment Breakdown by Category
Other$1.1M (60.1%)
Consulting$447,363 (23.4%)
Travel$235,019 (12.3%)
Research$42,120 (2.2%)
Food & Beverage$36,885 (1.9%)
Education$79.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 397 | 57.5% |
| Consulting Fee | $447,363 | 158 | 23.4% |
| Travel and Lodging | $235,019 | 580 | 12.3% |
| Honoraria | $49,682 | 18 | 2.6% |
| Unspecified | $42,120 | 15 | 2.2% |
| Food and Beverage | $36,885 | 508 | 1.9% |
| Education | $79.24 | 4 | 0.0% |
Payments by Type
General
$1.9M
1,665 transactions
Research
$42,120
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $559,041 | 566 | $0 (2024) |
| Janssen Biotech, Inc. | $194,889 | 240 | $0 (2024) |
| Foundation Medicine, Inc. | $192,796 | 53 | $0 (2023) |
| EMD Serono, Inc. | $175,608 | 128 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $126,803 | 102 | $0 (2024) |
| Merck Sharp & Dohme LLC | $117,069 | 134 | $0 (2024) |
| Mirati Therapeutics, Inc. | $74,591 | 47 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $69,653 | 73 | $0 (2024) |
| Daiichi Sankyo Inc. | $59,429 | 48 | $0 (2024) |
| Amgen Inc. | $55,661 | 58 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $481,027 | 408 | AstraZeneca Pharmaceuticals LP ($135,974) |
| 2023 | $488,176 | 442 | AstraZeneca Pharmaceuticals LP ($153,959) |
| 2022 | $252,677 | 223 | Janssen Biotech, Inc. ($89,423) |
| 2021 | $145,184 | 82 | Foundation Medicine, Inc. ($59,900) |
| 2020 | $98,426 | 54 | Takeda Pharmaceuticals U.S.A., Inc. ($31,500) |
| 2019 | $188,454 | 185 | AstraZeneca Pharmaceuticals LP ($74,749) |
| 2018 | $121,582 | 139 | AstraZeneca Pharmaceuticals LP ($63,350) |
| 2017 | $132,696 | 147 | E.R. Squibb & Sons, L.L.C. ($70,085) |
All Payment Transactions
1,680 individual payment records from CMS Open Payments — Page 1 of 68
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| 12/26/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 12/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,330.00 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,720.00 | General |
| 12/19/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $2,740.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $4,987.50 | General |
| Category: Oncology | ||||||
| 12/18/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,830.00 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 12/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $101.49 | General |
| Category: Oncology | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $620.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/10/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $516.57 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/10/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $49.96 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,290.00 | General |
| 12/08/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $102.22 | General |
| 12/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug), AKEEGA | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $46.76 | General |
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $6.60 | General |
| Category: Oncology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,400.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $466.96 | General |
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $961.46 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $100.37 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $51.55 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | Cash or cash equivalent | $49.85 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $48.82 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS | Takeda Pharmaceuticals U.S.A., Inc. | $31,500 | 7 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| REGN3767 CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,020 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 290 | 1,267 | $580,118 | $141,005 |
| 2022 | 4 | 234 | 1,065 | $452,331 | $121,419 |
| 2021 | 4 | 159 | 933 | $392,597 | $106,567 |
| 2020 | 6 | 216 | 845 | $278,354 | $57,235 |
Total Patients
899
Total Services
4,110
Medicare Billing
$426,227
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 125 | 763 | $363,476 | $88,388 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 83 | 315 | $150,735 | $36,673 | 24.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 144 | $35,712 | $9,384 | 26.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 33 | 33 | $21,939 | $4,846 | 22.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $8,256 | $1,715 | 20.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 114 | 810 | $351,540 | $95,353 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 53 | 119 | $51,646 | $14,401 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 93 | $23,064 | $5,504 | 23.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $17,825 | $4,194 | 23.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $8,256 | $1,967 | 23.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 96 | 800 | $352,562 | $96,334 | 27.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 88 | $21,226 | $5,289 | 24.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 24 | 24 | $14,420 | $3,455 | 24.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 15 | 21 | $4,389 | $1,488 | 33.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 80 | 530 | $177,020 | $33,236 | 18.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 33 | 152 | $33,744 | $8,387 | 24.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 40 | 78 | $34,944 | $6,880 | 19.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 27 | 49 | $9,986 | $3,262 | 32.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 20 | 20 | $12,740 | $2,747 | 21.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $9,920 | $2,725 | 27.5% |
About Dr. Hatim Husain, MD
Dr. Hatim Husain, MD is a Internal Medicine healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2008. The National Provider Identifier (NPI) number assigned to this provider is 1629234109.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hatim Husain, MD has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $481,027 received in 2024. These payments were reported across 1,680 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Husain has provided services to 899 Medicare beneficiaries, totaling 4,110 services with total Medicare billing of $426,227. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location San Diego, CA
- Active Since 08/04/2008
- Last Updated 11/14/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1629234109
Products in Payments
- TAGRISSO (Drug) $376,976
- RYBREVANT (Drug) $201,155
- FOUNDATIONONE CDX (Device) $146,375
- IMFINZI (Biological) $125,868
- OPDIVO (Biological) $110,832
- KEYTRUDA (Biological) $100,821
- TEPMETKO (Drug) $95,179
- LIBTAYO (Biological) $86,370
- KRAZATI (Drug) $74,591
- ZEPZELCA (Drug) $51,451
- Enhertu (Drug) $45,430
- LUMAKRAS (Drug) $44,473
- FOUNDATIONONE LIQUID (Device) $44,272
- GAVRETO (Drug) $30,030
- IMFINZI (Drug) $26,311
- BAVENCIO (Drug) $23,818
- HealthTec (Device) $17,418
- ENHERTU (Biological) $11,562
- Vitrakvi (Drug) $5,800
- Rezlidhia (Drug) $5,218
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Diego
Dr. Bob Geng, M.d, M.D
Internal Medicine — Payments: $3.0M
Internal Medicine $3.0M
Dr. Steven Edelman, M.d, M.D
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Dr. Gary Firestein, M.d, M.D
Internal Medicine — Payments: $902,808
Internal Medicine $902,808
Dr. Adam Zweig, Md, MD
Internal Medicine — Payments: $385,670
Internal Medicine $385,670
Dr. James Breitmeyer
Internal Medicine — Payments: $362,929
Internal Medicine $362,929
Dr. Bernard Michlin, M.d, M.D
Internal Medicine — Payments: $297,383
Internal Medicine $297,383